GSK to buy rare cancer drug developer IDRx for up to £1bn - MSN

GSK To Buy Rare Cancer Drug Developer IDRx For Up To £1bn - MSN

2 weeks from now

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts …

msn.com

GSK Buys US-based Rare Cancer Treatment Developer For Up To £1bn

2 weeks from now

2 days ago  · Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said …

independent.co.uk

GSK Targets Rare Cancer With $1B+ Acquisition Of IDRx

2 weeks from now

2 days ago  · GSK fired the opening gun for the 2025 JP Morgan Healthcare Conference on Monday with a front-loaded acquisition agreement, moving to buy precision therapy specialist …

biospace.com

GSK To Buy US Cancer Biotech IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago  · GSK Plc agreed to buy US biotech IDRx for as much as $1.15 billion to gain new cancer medicines.. The UK drugmaker will pay $1 billion upfront for IDRx, whose lead drug for …

bloomberg.com

GSK To Buy IDRx For $1B, Picking Up GI Cancer Drug - STAT

2 weeks from now

2 days ago  · LONDON — Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront. The deal, which includes another …

statnews.com

Is GSK Prepping A $1bn Takeover Bid For IDRx? | Pharmaphorum

2 weeks from now

6 days ago  · Neither GSK nor IDRx has commented on the rumoured negotiations. GIST is a rare cancer, but still the most common subtype of soft tissue sarcoma occurring in the …

pharmaphorum.com

GSK Buys American Firm Developing Therapy For Rare Tumours

2 weeks from now

GSK has agreed an acquisition worth up to $1.15 billion for IDRx, an American biopharmaceutical company. ... It gives GSK access to IDRx’s lead molecule being developed for the treatment of …

thetimes.com

GSK Nears $1bn Deal For Biotech Developing Drug For Rare Tumour

2 weeks from now

Jan 8, 2025  · Sales of cancer drugs at GSK increased 94 per cent year on year to more than $1bn in the first three quarters of 2024. This included a contribution from the drug Ojjaara, …

ft.com

GSK Nearing Deal To Acquire US Biotech IDRx For Up To $1 Billion

2 weeks from now

Jan 8, 2025  · -- GSK is in advanced discussions to acquire privately-owned US biotech company IDRx for up to $1 billion, the Financial Times reported Wednesday, citing people close to the …

marketscreener.com

GSK Nears $1B Deal To Buy U.S. Biotech IDRx (GSK:NYSE)

2 weeks from now

Jan 8, 2025  · British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The …

seekingalpha.com

GSK Nears Deal To Acquire US Biotech IDRx For Up To $1 Billion

2 weeks from now

Jan 8, 2025  · -- GSK is in advanced discussions to acquire closely held US biotech company IDRx for up to $1 billion, the Financial Times reported Wednesday, citing people close to the …

marketscreener.com

GSK To Buy U.S. Rare Tumor Specialist IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago  · GSK is buying privately-owned U.S. rare-tumor specialist IDRx for up to $1.15 billion, boosting its gastrointestinal cancer portfolio. The pharmaceutical giant said Monday that it will …

marketscreener.com

GSK In Talks To Buy U.S. Rare Tumor Specialist IDRx For Up To $1 ...

2 weeks from now

6 days ago  · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 …

morningstar.com

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

Jan 8, 2025  · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. Backed by a raft of …

proactiveinvestors.com

GSK Is Said To Be Nearing $1B Deal To Acquire U.S. Biotech IDRx

2 weeks from now

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The Financial Times …

msn.com

GSK Nears $1 Billion Deal For Biotech Company IDRx - MSN

2 weeks from now

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio.

msn.com

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

6 days ago  · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. ...

proactiveinvestors.com.au

GSK Close To US$1b Deal For Biotech Company IDRx, Bloomberg …

2 weeks from now

6 days ago  · GSK plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology …

theedgemalaysia.com

GSK In Talks To Buy U.S. Rare Tumor Specialist IDRx For Up To $1 ...

2 weeks from now

6 days ago  · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 …

marketscreener.com

GSK Nearing $1 Billion Deal To Acquire US Biotech IDRx, FT Reports

2 weeks from now

Jan 8, 2025  · GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 Billion, FT Says, Citing Sources ... Gsk Plc's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives US …

marketscreener.com